These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 19276664)

  • 1. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants.
    Narang A; Bose A; Pandit AN; Dutta P; Kang G; Bhattacharya SK; Datta SK; Suryakiran PV; Delem A; Han HH; Bock HL
    Hum Vaccin; 2009 Jun; 5(6):414-9. PubMed ID: 19276664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants.
    Li RC; Huang T; Li Y; Wang LH; Tao J; Fu B; Si G; Nong Y; Mo Z; Liao X; Luan I; Tang H; Rathi N; Karkada N; Han HH
    Hum Vaccin Immunother; 2016 Mar; 12(3):785-93. PubMed ID: 27149266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
    Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
    Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
    Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
    J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.
    Li RC; Li YP; Mo ZJ; Luo D; Huang T; Kong JL; Wang LH; Song NS; Liu A; Zhang H; Liao X; Karkada N; Han HH
    Hum Vaccin Immunother; 2013 Aug; 9(8):1638-42. PubMed ID: 23807360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
    J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
    Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
    Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa.
    Steele AD; Madhi SA; Louw CE; Bos P; Tumbo JM; Werner CM; Bicer C; De Vos B; Delem A; Han HH
    Pediatr Infect Dis J; 2011 Feb; 30(2):125-30. PubMed ID: 20842070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe.
    Vesikari T; Karvonen A; Prymula R; Schuster V; Tejedor JC; Thollot F; Garcia-Corbeira P; Damaso S; Han HH; Bouckenooghe A
    Vaccine; 2010 Jul; 28(32):5272-9. PubMed ID: 20538094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
    Salinas B; Pérez Schael I; Linhares AC; Ruiz Palacios GM; Guerrero ML; Yarzábal JP; Cervantes Y; Costa Clemens S; Damaso S; Hardt K; De Vos B
    Pediatr Infect Dis J; 2005 Sep; 24(9):807-16. PubMed ID: 16148848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
    Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
    Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a three dose and five dose oral human rotavirus vaccine (RIX4414) schedule in south Indian infants.
    Kompithra RZ; Paul A; Manoharan D; Babji S; Sarkar R; Mathew LG; Kang G
    Vaccine; 2014 Aug; 32 Suppl 1():A129-33. PubMed ID: 25091666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.
    Kawamura N; Tokoeda Y; Oshima M; Okahata H; Tsutsumi H; Van Doorn LJ; Muto H; Smolenov I; Suryakiran PV; Han HH
    Vaccine; 2011 Aug; 29(37):6335-41. PubMed ID: 21640780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.
    Kim JS; Bae CW; Lee KY; Park MS; Choi YY; Kim KN; Kim JD; Park WS; Sin JB; Kim EA; Lee SG; Kim CS; Cha SH; Hong YJ; Shin SM; Shim GH; Choi KM; Yang JW; Liu A; Suryakiran PV; Han HH
    Hum Vaccin Immunother; 2012 Jun; 8(6):806-12. PubMed ID: 22699440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
    Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
    Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial.
    Lau YL; Nelson EA; Poon KH; Chan PK; Chiu S; Sung R; Leung CW; Ng D; Ma YM; Chan D; Lee TL; Tang J; Kwan YW; Ip P; Ho M; Fung LW; Tang H; Suryakiran PV; Han HH; Bock H;
    Vaccine; 2013 Apr; 31(18):2253-9. PubMed ID: 23499605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.
    Cunliffe NA; Witte D; Ngwira BM; Todd S; Bostock NJ; Turner AM; Chimpeni P; Victor JC; Steele AD; Bouckenooghe A; Neuzil KM
    Vaccine; 2012 Apr; 30 Suppl 1(0 1):A36-43. PubMed ID: 22520135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 °C for seven days.
    Kerdpanich A; Chokephaibulkit K; Watanaveeradej V; Vanprapar N; Simasathien S; Phavichitr N; Bock HL; Damaso S; Hutagalung Y; Han HH
    Hum Vaccin; 2011 Jan; 7(1):74-80. PubMed ID: 21228629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China.
    Li RC; Huang T; Li Y; Luo D; Tao J; Fu B; Si G; Nong Y; Mo Z; Liao X; Luan I; Tang H; Rathi N; Karkada N; Han HH
    Hum Vaccin Immunother; 2014; 10(1):11-8. PubMed ID: 24013441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants.
    Araujo EC; Clemens SA; Oliveira CS; Justino MC; Rubio P; Gabbay YB; da Silva VB; Mascarenhas JD; Noronha VL; Clemens R; Gusmão RH; Sanchez N; Monteiro TA; Linhares AC
    J Pediatr (Rio J); 2007; 83(3):217-24. PubMed ID: 17380232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.